The new frontier of cancer neuroscience
Understanding complex interactions between cancer and the nervous system may offer new insights into the mechanisms that drive tumour progression
Early signs of progress in osteosarcoma research
Emerging molecular and spatial approaches are providing new insights into osteosarcoma and identifying potential targets for future therapies
From bottleneck to breakthrough: rethinking clinical data collection in the age of AI
Every day, clinicians generate thousands of reports containing critical data that will never be analysed. Not because it lacks value — but because extracting it remains a bottleneck.
ctDNA is unlocking new clinical opportunities for liquid biopsy
Testing standardisation and optimal integration for routine clinical use remain challenging
Multimodal AI biomarkers: from biology to patient stratification
Artificial intelligence is enabling a new class of biomarkers by integrating histology, molecular data, imaging, and clinical records to generate scalable, biologically grounded insights for precision oncology.
Why AI-powered trial matching alone will not fix oncology trial recruitment
AI-powered trial matching helps identify relevant trials faster, but recruitment often fails beyond the algorithm. Limited cross-site trial discovery, outdated recruitment information and fragmented referral pathways continue to prevent potentially eligible patients from participating in relevant trials.
Overcoming resistance to immunotherapy in NSCLC?
Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC
What is the way forward for undruggable tumour targets?
2026 ESMO TAT Honorary Awardee, Prof. Timothy A. Yap, sees a bright future ahead for novel synthetic lethal strategies, driven by advances in technology and novel biomarkers
Bridging the interpretation gap in cancer genomics – the next frontier for AI in oncology
Can artificial intelligence finally unlock the full potential of cancer genomics? Discover how new digital tools are closing the gap between data and clinical action in oncology.
Triple combination with radioligand therapy improves radiographic progression-free survival in metastatic prostate cancer
Presidential Symposium presentation provides insights into the role of 177Lu-PSMA-617 in the treatment of hormone-sensitive prostate cancer, with results also presented in castration-resistant disease